Phosphodiesterase-5 Inhibitor Therapy for Pulmonary Hypertension in the United States. Actual versus Recommended Use

Annals of the American Thoracic Society
Deborah KimRenda S Wiener

Abstract

Care of patients with pulmonary hypertension is complex. Although pulmonary vasodilators are effective for Group 1 pulmonary hypertension, clinical guidelines and the Choosing Wisely Campaign recommend against routine use for Groups 2 and 3 pulmonary hypertension (the most common types of pulmonary hypertension) because of a lack of benefit, potential for harm, and high cost ($10,000-$13,000 per patient per year treated). Little is known about how these medications are used in practice. To determine national patterns of phosphodiesterase-5 inhibitor prescribing for pulmonary hypertension in the Veterans Health Administration. Retrospective analysis of Veterans prescribed phosphodiesterase-5 inhibitor for pulmonary hypertension between 2005 and 2012 at any Veterans Health Administration site. Patients were identified by presence of an International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis code for pulmonary hypertension and one or more outpatient prescriptions for daily phosphodiesterase-5 inhibitor therapy. We developed and validated, using gold-standard chart abstraction, an International Classification of Diseases, Ninth Revision, Clinical Modification-based algorithm to assign pulmonary hyp...Continue Reading

References

Oct 27, 1999·JAMA : the Journal of the American Medical Association·M D CabanaH R Rubin
Apr 16, 2005·American Journal of Respiratory and Critical Care Medicine·Ari ChaouatEmmanuel Weitzenblum
Oct 4, 2005·Social Science & Medicine·Helen Prosser, Tom Walley
May 2, 2008·The European Respiratory Journal·D StolzM Tamm
Jan 24, 2009·American Journal of Respiratory and Critical Care Medicine·Micah R FisherPaul M Hassoun
Oct 31, 2009·American Journal of Respiratory and Critical Care Medicine·Isabel BlancoJoan Albert Barberà
Jan 23, 2010·Respiratory Medicine·Omar A MinaiJames K Stoller
Apr 12, 2012·JAMA : the Journal of the American Medical Association·Christine K Cassel, James A Guest
Aug 14, 2012·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·James C FangRaymond L Benza
Feb 23, 2013·The European Respiratory Journal·Isabel BlancoJoan Albert Barberà
Mar 13, 2013·JAMA : the Journal of the American Medical Association·Margaret M RedfieldUNKNOWN RELAX Trial
Jul 3, 2013·Circulation. Heart Failure·Bradley A MaronJayashri R Aragam
Dec 21, 2013·Journal of the American College of Cardiology·Jean-Luc VachiéryWerner Seeger
Dec 21, 2013·Journal of the American College of Cardiology·Werner SeegerJean-Luc Vachiéry
Dec 21, 2013·Journal of the American College of Cardiology·Marius M HoeperDavid B Badesch
Jan 9, 2014·Implementation Science : IS·Vinay Prasad, John Pa Ioannidis
Apr 5, 2014·Chest·Mary G GeorgeShaleah Levant
Feb 11, 2015·Journal of General Internal Medicine·Shirley MusichCharlotte S Yeh
Mar 19, 2015·Circulation. Heart Failure·Barry A BorlaugMargaret M Redfield
May 23, 2015·Journal of Telemedicine and Telecare·Varsha G VimalanandaSteven R Simon
Feb 6, 2016·Journal of the American College of Cardiology·Alexander PapolosPartho P Sengupta

❮ Previous
Next ❯

Citations

Jun 2, 2018·Annals of the American Thoracic Society·Peter J LearyTim Lahm
May 13, 2020·Circulation. Cardiovascular Quality and Outcomes·Kari R GillmeyerRenda Soylemez Wiener
Mar 10, 2020·Annals of the American Thoracic Society·Kari R GillmeyerRenda Soylemez Wiener
Mar 16, 2021·Journal of the American Heart Association·Manreet K KanwarVallerie McLaughlin

❮ Previous
Next ❯

Related Concepts

Related Feeds

American Thoracic Association Journals

Discover the latest respiratory research published by the journals from the American Thoracic Society.